The present invention includes novel compositions and methods for treating comprising a compound with the Formula I:

##STR00001##

wherein n=0, 1, 2, 3, 4, or 5; X=NH or O or S; Y=phenyl, or a phenyl group substituted with at least one methyl, a phenyl group substituted with at least one nitro, a phenyl group substituted with at least one nitrogen, a phenyl group substituted with at least one boron, aryl, substituted aryl, heteroaryl, four to six membered cycloalkyl, four to six membered heterocycloalkyl; R=H, C(O)R.sub.2, SO.sub.2R.sub.2; R.sub.1=H, C(O)R.sub.2, SO.sub.2R.sub.2; R.sub.2=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, NH.sub.2, NR.sub.3R.sub.4; R.sub.3, R.sub.4=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, three to six membered cycloalkyl, and Z=NH, or O, or none, and optionally wherein both X and Z are not both S, and wherein the amount of the compound is selected to either inhibit or activate the immune response.

The present invention includes novel compositions and methods for treating comprising a compound with the Formula I:

##STR00001##

wherein n=0, 1, 2, 3, 4, or 5; X=NH or O or S; Y=phenyl, or a phenyl group substituted with at least one methyl, a phenyl group substituted with at least one nitro, a phenyl group substituted with at least one nitrogen, a phenyl group substituted with at least one boron, aryl, substituted aryl, heteroaryl, four to six membered cycloalkyl, four to six membered heterocycloalkyl; R=H, C(O)R.sub.2, SO.sub.2R.sub.2; R.sub.1=H, C(O)R.sub.2, SO.sub.2R.sub.2; R.sub.2=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, NH.sub.2, NR.sub.3R.sub.4; R.sub.3, R.sub.4=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, three to six membered cycloalkyl, and Z=NH, or O, or none, and optionally wherein both X and Z are not both S, and wherein the amount of the compound is selected to either inhibit or activate the immune response.

A composition is based on N-palmitoyl-ethanolamide and Baicalein in the co-micronized form. The includes a mixture of palmitoyl-ethanolamide (PEA) and Baicalein in co-micronized form. The composition is usable for treating benign prostatic hyperplasia.

A composition is based on N-palmitoyl-ethanolamide and Baicalein in the co-micronized form. The includes a mixture of palmitoyl-ethanolamide (PEA) and Baicalein in co-micronized form. The composition is usable for treating benign prostatic hyperplasia.

The present invention relates to divalent compounds binding to LecA. The compounds are useful to block biofilm formation of Pseudomonas aeruginosa. The invention further relates to pharmaceutical compositions comprising these compounds and to therapeutic methods and uses of these compounds, in particular to therapeutic methods and uses for the treatment of Pseudomonas aeruginosa infections in a subject. The invention also relates to imaging of infections, such as biofilms produced by Pseudomonas aeruginosa, by using these divalent compounds.

The present invention relates to divalent compounds binding to LecA. The compounds are useful to block biofilm formation of Pseudomonas aeruginosa. The invention further relates to pharmaceutical compositions comprising these compounds and to therapeutic methods and uses of these compounds, in particular to therapeutic methods and uses for the treatment of Pseudomonas aeruginosa infections in a subject. The invention also relates to imaging of infections, such as biofilms produced by Pseudomonas aeruginosa, by using these divalent compounds.

Disclosed herein are tucaresol derivative compound and composition containing the same. Also disclosed herein are methods of enhancing immune response in a subject by administering the tucaresol derivative compound or by co-administering the tucaresol derivative compound and one or more additional agents. Also disclosed herein are use of the tucaresol derivative compound and composition containing the same in the manufacture of a medicament for treating cancer or enhancing immune response in a subject.

Disclosed herein are tucaresol derivative compound and composition containing the same. Also disclosed herein are methods of enhancing immune response in a subject by administering the tucaresol derivative compound or by co-administering the tucaresol derivative compound and one or more additional agents. Also disclosed herein are use of the tucaresol derivative compound and composition containing the same in the manufacture of a medicament for treating cancer or enhancing immune response in a subject.

The present invention provides a preventing or improving agent that can favorably promote bone formation, is effective in preventing or improving osteoporosis or a decrease in bone strength, has high safety, and is suitable for long-term continuous ingestion or administration, by forming a bone remodeling accelerator comprising one or more kinds selected from the group consisting of flavanone and a glycoside thereof.

A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.